Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · Real-Time Price · USD
1.130
-0.020 (-1.74%)
Jan 22, 2025, 9:37 AM EST - Market open
Achilles Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Buy
Price Target
$4.00
Upside
+253.98%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +76.99% | Apr 5, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $11 → $6 | Strong Buy | Maintains | $11 → $6 | +430.97% | Apr 5, 2024 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $7 → $0.5 | Strong Buy → Sell | Downgrades | $7 → $0.5 | -55.75% | Dec 14, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +873.45% | Aug 7, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +873.45% | May 11, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +1,404.42% | Dec 7, 2022 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8 | Buy | Maintains | $10 → $8 | +607.96% | Dec 7, 2022 |
| JP Morgan | JP Morgan | Sell Initiates $11 | Sell | Initiates | $11 | +873.45% | Apr 26, 2021 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +2,289.38% | Apr 26, 2021 |
| Piper Sandler | Piper Sandler | Buy Initiates $25 | Buy | Initiates | $25 | +2,112.39% | Apr 26, 2021 |
| Oppenheimer | Oppenheimer | Buy Initiates $23 | Buy | Initiates | $23 | +1,935.40% | Apr 26, 2021 |